Does cardiovascular protection translate into renal protection? (Q42670795)

4 November 2017

title

Does cardiovascular protection translate into renal protection? (English)

1 reference

4 November 2017

Gema Ruiz-Hurtado

1

0 references

Luis Miguel Ruilope

object named as

Luis M Ruilope

series ordinal

2

0 references

language of work or name

English

0 references

publication date

8 July 2014

1 reference

Nature Reviews Cardiology

4 November 2017

published in

1 reference

4 November 2017

volume

11

1 reference

4 November 2017

issue

12

1 reference

4 November 2017

page(s)

742-746

1 reference

Renal function and target organ damage in hypertension

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Global burden of blood-pressure-related disease, 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Prehypertension and Incidence of ESRD: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Lowering blood pressure reduces renal events in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Combined angiotensin inhibition for the treatment of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Changes in albuminuria predict mortality and morbidity in patients with vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

RETRACTED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Chronic kidney disease: Blood pressure control in CKD--still a matter of debate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: A 5,693-patient cross-sectional analysis from Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

21 January 2018

Leptin and renal disease

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Low eGFR and high albuminuria predict end stage kidney disease and death at all ages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

High prevalence of masked uncontrolled hypertension in people with treated hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

Renal and cardiovascular events: do they deserve the same consideration in clinical trials?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2014.97

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification

31 March 2020

1 reference

12 December 2020

Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study

1 reference

12 December 2020

Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus

1 reference

12 December 2020

Current drug development challenges in chronic kidney disease (CKD)--identification of individualized determinants of renal progression and premature cardiovascular disease (CVD)

1 reference

12 December 2020

Hypertension in middle-aged men. Management, morbidity and prognostic factors during long-term hypertensive care

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRCARDIO.2014.97

1 reference

4 November 2017

1 reference